Q-omics provides the consensus-scored LGALS4 profile across patient tissues and cancer cell-line models. LGALS4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LGALS4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, LGALS4 RNA expression shows 17,572 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where LGALS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALS4 survival associations across molecular data types. LGALS4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALS4 RNA expression–survival associations across cancer types. High LGALS4 expression shows unfavorable associations in ACC, KIRP and MESO, but favorable associations in KIRC, UCS and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LGALS4 RNA expression.
This table summarizes LGALS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LGALS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALS4 shows lower tumor expression in COAD, LUSC, KICH, READ and UCEC and higher tumor expression in KIRC. The COAD box plot shows higher LGALS4 RNA expression in normal versus tumor tissue (log2 FC = −1.913, t-test p < 0.001).
This table shows molecular features associated with LGALS4 in patient tissues and cancer cell lines. In patient samples, LGALS4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LGALS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
